EBITDA grew 37 per cent YoY to Rs 1,065 million
OneSource Pharma has registered Q2FY26 results. The company registered a revenue growth of 12 per cent and margin expansion of 506 bps YoY. The company posted revenues at Rs 3,758 million, up 12 per cent YoY. The EBITDA grew 37 per cent YoY to Rs 1,065 million, EBITDA margin of 28 per cent, an expansion of ~506 bps YoY and adjusted PAT stood at Rs 449 million with adjusted EPS of Rs 3.9.
Neeraj Sharma, CEO and MD, OneSource Specialty Pharma speaking on the performance said, “Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity addition is being accelerated to support upcoming customer launches. We are excited about recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India and accordingly are raising our FY28 revenue outlook to $500m+."
